Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”
Pamukkale Medical Journal · 10.07.2026 · 19 (3) · 666-667
DOI: 10.31362/patd.1948929 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pamukkale Medical Journal, online erschienen am 10.07.2026. Verfasst von Siahmet Atlı. Die Arbeit nennt 6 Literaturangaben.
Themen: COPD
Abstract (Originalsprache)
Asthma-COPD overlap (ACO) is a controversial concept without a universally accepted definition. In the study by Aslan and Enli, ACO was defined based on airflow limitation and reversibility; however, this approach may not fully reflect current guideline perspectives. Recent GINA and GOLD reports emphasize a phenotype-based approach rather than defining ACO as a distinct disease entity. Therefore, the observed limited diagnostic value of prostaglandin D2 (PGD2) may be influenced by methodological limitations, particularly patient selection and classification strategy.
Zitieren
APA
Atlı, S. (2026). Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”. Pamukkale Medical Journal, 19(3), 666-667. https://doi.org/10.31362/patd.1948929
Vancouver
Atlı S. Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”. Pamukkale Medical Journal. 2026;19(3):666-667. doi:10.31362/patd.1948929
BibTeX
@article{Atl2026,
author = {Atlı, Siahmet},
title = {Comment on: “The prevalence of asthma-COPD overlap (ACO) among COPD patients and the role of prostaglandin D2 (PGD2) in differential diagnosis”},
journal = {Pamukkale Medical Journal},
year = {2026},
volume = {19},
number = {3},
pages = {666--667},
doi = {10.31362/patd.1948929}
}
EUVIMED